advanced search

The Subcutaneous Drug Development & Delivery Consortium

The Subcutaneous Drug Development & Delivery Consortium was established in 2018 to improve subcutaneous drug development and delivery fundamentally, addressing key issues in the subcutaneous industry and expanding subcutaneous technology use to improve patient outcomes.


Visit Website

Headquarters
The Subcutaneous Drug Development & Delivery Consortium
3855 SW 153rd Drive
Beaverton
OR 97003
United States

Phone / Contact

E: [email protected]

Connect

The Subcutaneous Drug Development & Delivery Consortium (“SC Consortium”) was established in 2018 to improve subcutaneous drug development and delivery fundamentally. Motivated by this shared goal, the organisations within the Consortium’s membership have come together to address key issues in the subcutaneous industry and expand subcutaneous technology use to improve patient outcomes.

Article

PHARMA VIEW
Conor O'Neill
ADOPTION OF SUSTAINABILITY PRACTICES WITHIN SUBCUTANEOUS DRUG DELIVERY: INDUSTRY INSIGHTS
Conor O’Neill (GSK), Duncan Paterson (AstraZeneca) and Dr Monica Adams (GSK) come together to discuss a recent study conducted by the Subcutaneous Drug Development & Delivery Consortium among its member organisations, digging into the pharmaceutical industry’s progress and priorities when it comes to improving the environmental impact of subcutaneous medicines.
Top